VICTORIA, BC, Jan. 23, 2017 /CNW/ - Emerald Health Therapeutics Inc. (TSXV: EMH) ("Emerald" or the "Company") is pleased to announce that management will present at Canaccord Genuity's inaugural Cannabis Investor Day on Thursday, January 26, 2017 at 3:10 p.m. Pacific Time. The conference will be taking place at the Fairmont Waterfront Hotel in Vancouver, BC.
"We believe cannabinoid medicines present an unparalleled opportunity for use as adjuvants (supplements) or replacements to a host of conventional pharmaceutical medicines that are typically much more toxic and potentially less efficacious. As an example, a therapeutic alternative to opiates. It's with that in mind that we remain focused on developing high quality cannabis-based medicines, backed by clinical efficacy, with standard dosing and conventional delivery mechanisms. We look forward to sharing this vision and participating in Canaccord Genuity's event," says Avtar Dhillon, M.D., Executive Chairman of Emerald.
For additional information on the event, please contact your Canaccord Genuity representative.
Join us on our journey of making lives better through cannabis science.
For more information, explore our website and investor presentation here (www.emerald.care/about)
ON BEHALF OF THE BOARD
Emerald Health Therapeutics Inc.
Emerald Health Therapeutics is a Licensed Producer under ACMPR, capable of cultivating and selling both dried medical cannabis flower and medical cannabis oils in Canada. Emerald operates out of a GMP-compliant indoor facility in Victoria, British Columbia, with plans for a 32 acre purpose built hybrid greenhouse expansion in metro Vancouver. Emerald prides itself on being one of Canada's most medically focused producers with amongst the most pharmaceutically qualified management teams in the industry. We aim to capture unique corners of both the medical and future recreational cannabis market through proprietary strains, defensible intellectual property, and superb patient and consumer experience.
SOURCE Emerald Health Therapeutics, Inc.